What To Do With Underperforming Investment Trusts

Have you ever opened a holdings list, spotted a name that used to look clever, and felt that quiet drop in the stomach? I have. More than once. An investment trust that once sat near the top of its peer group can slide for years, and the temptation is either to pretend it is fine or to dump it in a mood. Neither habit is particularly grown-up.

When A Trust Stops Earning Its Place

The awkward truth is that underperforming investment trusts are part of ordinary portfolio life. Closed-end funds live in public, their discounts flash on a screen, and boards cannot hide forever. Still, selling just because the last three years look ugly can be as costly as clinging on because you liked the story in 2019.

Patience sometimes pays. A well-known global growth vehicle went from hero to zero and then climbed back toward the front of its three-year table. That recovery was not magic. The style that had been punished came back into fashion, and the manager had not abandoned the process that built the earlier record. Contrast that with a European specialist that never really recovered after its largest holding imploded. The thesis was broken. The vehicle later disappeared into a merger. Same surface problem, very different ending.

Poor results caused by a sector, a style, or a region being out of favour are often worth living with. Poor results with no excuse, a rigid process, or a thesis that no longer holds are usually a reason to walk away.

That split is the whole job. Not a slogan. A checklist you apply name by name.

Separate Style Pain From Manager Failure

Markets run in moods. Growth can dominate for a long stretch, then value wakes up. Defensive multi-asset funds can look wise in a scare and foolish in a grind higher. If a trust is built to own quality compounders, or deep value, or cash-heavy wealth preservation, a lag during the opposite regime is not automatically a firing offence.

I have found it useful to ask a blunt question. Would I still buy this process today if the recent numbers were average rather than bad? If the answer is yes, the lag may be cyclical. If the answer is no, you are paying rent on a story you no longer believe.

Look at value-tilted global trusts when growth is winning. A lag of tens of percentage points against a world index can look dreadful in a factsheet. It can also reverse quickly if corporate reform stories in cheaper markets start to pay, or if expensive winners finally stumble. That does not mean every value house deserves a free pass. It means you judge the investment process, the portfolio concentration, and whether the board still has a pulse.

• Style out of favour, process intact, board engaged: often hold or even add on a wide discount.
• Style in favour, process intact, numbers still weak: dig harder into stock picking and costs.
• Style excuse used every year, process drifting, board silent: treat that as a sell signal.

Global Names That Force A Decision

The global sector is crowded, which is helpful. You can compare like with like instead of inventing excuses. One former favourite that changed manager stables a few years ago has since delivered a weak mid-teens total return while a world equity index marched far ahead. When a switch was meant to fix the problem and the gap only widened, the board cannot keep repeating the same press-release optimism. Another move is not guaranteed. It is, however, the conversation shareholders should force.

Defensive income and wealth-preservation trusts sit in a different psychological box. Returns in the mid-teens over three years look poor beside equity bulls. The managers rarely hide their caution. If you bought them to sleep at night, you cannot honestly claim surprise. The risk is different. Years of waiting for a great bear market can become a habit. Capital that sits in a defensive wrapper still has an opportunity cost. In my experience, investors stay loyal here longer than the numbers justify, because the marketing language feels adult and responsible.

Then there is the multi-manager experiment: a roster of high-conviction sleeves, each capped at a short list of names, sold as complementary elites. On paper it sounds diversified and clever. In practice, overlapping risk and extra complexity can produce a muddle. When a simpler, long-standing global trust compounds faster with less theatre, the comparison is uncomfortable. Switching is not disloyal. It is housekeeping.

Income-labelled global growth houses create another mismatch. A house famous for growth can be asked to run a dividend franchise that needs banks, energy, and utilities when those groups rally. Missing those recoveries while advertising a multi-decade dividend streak is a branding win and an investment problem. A sub-3% yield after years of rising payouts is not a crime. It is a hint that the share price has not been rewarded for the income story, or that the equity style never fitted the mandate.

Give A Proven Manager Room, Not Forever

UK equity income and growth trusts have an oversupply problem. That is polite language for too many vehicles chasing a market that has been unloved. A once-stellar consumer-quality specialist can post near-flat three- and five-year numbers and still tell a persuasive story about brands, cash flow, and a portfolio that has evolved without being abandoned. I think that kind of manager deserves a longer leash than a new hire with a thin record. Benefit of the doubt is not a blank cheque. It is a timed review.

Set a date. Write down what improvement would look like: relative return versus the All-Share, versus a chosen peer, and versus the manager’s own stated universe. If nothing turns by that date, sell. Hoping is not a process.

Small-cap UK trusts can fall from the top of their table to the bottom across a five-year window. That slide may reflect a genuine change in stock picking, or a market that punished the exact slice they own. Capital-and-income hybrids that lag the broad UK index across every listed time period are harder to defend. There is no shortage of alternatives. A trust that recently changed manager and already shows a lift is often a cleaner replacement than waiting for a sleepy board to discover urgency.

Boards exist to change managers, merge vehicles, buy back stock, and tell the truth about strategy. If they only publish warm words, shareholders should assume the lag will continue.

Europe, Asia, And The Specialist Corner

A long-running European growth trust can look tired across one-, three-, and five-year windows even after a strong first decade and a half. Past glory is not a portfolio holding. If the same house still runs the money and the numbers keep slipping, the board should already be having a hard conversation. Shareholders should not wait to be invited.

Asia is messier because mandates differ: income, smaller companies, total return, country tilts. A laggard being absorbed by a stronger sibling is often the least bad ending. A former sister trust with an even weaker three-year record is not automatically cheap just because the discount looks wide. Compare it with a focused peer that compounded several times faster over the same stretch. That gap is information, not noise.

Among specialists, technology and resources have done the heavy lifting in recent years. A small-cap technology vehicle can still look left behind if the boom concentrated in mega-cap platforms. That is style again, not necessarily incompetence. Biotech start-up vehicles are a different animal. Wide discounts after a long journey from a charitable concept to a listed life-science investor can tempt people to average down. Sometimes the discount is a warning that the pipeline needs more time and more capital than public shareholders want to give. Selling late still beats selling never if the thesis has aged out.

Activist-style listed vehicles deserve their own footnote. A stretch of poor one- and three-year numbers can sit beside a history of violent recoveries. A third-off discount to net asset value is embarrassing for a high-profile founder. Embarrassment is not a catalyst by itself, but it can become one if buybacks, realizations, or a sharper public market tape arrive. This is one of the rare cases where adding on weakness can be rational, provided you already understand the concentration risk and the personality risk. If you do not, do not start your education in the hole.

Discounts, Dividends, And The Illusion Of Safety

A fat discount feels like a cushion. Sometimes it is. Sometimes it is a market saying the asset value is optimistic, the fee is stale, or the strategy is unloved for a reason. I still look at discounts, of course. I just refuse to treat a 20% or 30% gap as a free lunch.

1. Check whether the discount has been wide for years. Persistent cheapness is a verdict, not a gift.
2. Ask what would close it: a manager change, a continuation vote, a tender, or a merger.
3. Compare yield on price with yield on assets. A high share-price yield can mask a thin portfolio yield.
4. Read the dividend cover. A pretty streak of increases paid from income is healthier than one paid from capital as a habit.

Income investors love consecutive-year records. Fair enough. Compounding a payout for decades is not trivial. It still does not excuse missing entire industry recoveries if the mandate was income in the first place. Peers in global equity income have shown that you can own cash-generative cyclicals without turning into a trader. If your trust refuses those groups on philosophical grounds, own that choice. Do not pretend the lag is mysterious.

A Practical Sell, Hold, Or Add Framework

People like neat rules. Markets refuse to be neat. The framework below is still better than vibes.

Sell when the original thesis is dead, the manager has become inflexible, costs are high relative to a cleaner alternative, and the board has done nothing after a long enough trial. Sell when you would not repurchase the same shares tomorrow with fresh cash. That last test catches a surprising amount of nostalgia.

Hold when the lag matches a known style or regional winter, the portfolio still looks like the brochure, and you can name the conditions that would restore relative performance. Hold size should shrink if the position became large only because everything else rose.

Add only when three things line up: a process you still respect, a discount that is wide versus the trust’s own history rather than versus a fantasy, and a catalyst you can actually describe. “It is cheap” is not a catalyst. “Korea governance reform could re-rate a fifth of the book” is a catalyst, even if it may fail.

Decision sketch:
  1. Name the excuse in one sentence.
  2. Decide if that excuse is cyclical or structural.
  3. Pick a review date.
  4. Pre-commit to an action if nothing improves.

Write it down. Future-you will thank present-you when the next factsheet arrives and the narrative gets slippery again.

What Boards Can Do, And What You Should Demand

Closed-end structures give boards tools that open-ended funds lack. They can tender, buy back, change the manager, cut fees, tidy the mandate, or merge into a larger cousin. They can also sit still and collect fees while the discount yawns. Perhaps the most interesting aspect of the trust world is how uneven that courage is.

If performance has been poor through a full cycle and the same individuals still occupy the same chairs, assume inertia until proven otherwise. Letters that praise “engagement” without a timetable are decoration. Shareholders who attend meetings, vote against tired directors, and compare notes with other holders are not troublemakers. They are doing the job the structure requires.

Industry showcases and manager days can help, if you use them properly. Listen for specifics: position sizes, what they sold, what they got wrong, what would make them change their mind. Charm is cheap. A manager who can describe a mistake without rewriting history is usually a better bet than one who only recites the philosophy slide.

Costs, Overlap, And The Quiet Drag

Underperformance is not only about stock picks. Two global trusts can own many of the same mega-cap winners and still diverge because of fees, gearing, cash drag, and a handful of concentrated misses. Multi-manager sleeves add another layer of cost and correlation that factsheets underplay.

I have sat with portfolios that looked diversified on a pie chart and were, in practice, the same growth factor wearing different tickers. If three holdings are all waiting for the same style thaw, you do not have three ideas. You have one idea sized three times. Cutting the weakest expression of that idea is often enough. You do not always need a dramatic clear-out.

Gearing cuts both ways. It is lovely on the way up and rude on the way down. A lagging trust that stays geared into a style winter can dig a deeper hole than an ungeared peer with the same picks. Check the gearing policy before you decide the manager has “lost it.” Sometimes the balance sheet did the damage.

Taxes, Wrappers, And The Urge To Tinker

Inside a tax wrapper, selling a dud is emotionally easier and economically cleaner. Outside one, a crystallized loss can still be useful, but do not let the tax tail wag the investment dog. I have watched people hold a broken thesis for years to avoid a gain that was already large, then watch the gain shrink. That is not tax planning. That is paralysis with a spreadsheet.

Rebalancing after a sale matters. Cash that sits “until I find something” has a habit of becoming a permanent underweight to equities. If you exit a global laggard, have the replacement already on a shortlist: a simpler global compounder, a cheaper income peer, or a trust whose style is the one you actually want going forward. Decision first, broker ticket second.

Common Traps That Keep Duds In Portfolios

Anchoring on the purchase price. You do not get a medal for getting back to even. The market does not know what you paid.

Falling for the turnaround interview. A good talker can make a five-year lag sound like a coiled spring. Ask for the numbers that would falsify the story.

Confusing a dividend streak with skill. Paying a rising dividend is admirable. It can coexist with weak total returns if the capital account is asleep.

Treating every wide discount as mean-reverting. Some discounts are structural because the mandate is tiny, illiquid, or unfashionable. Size and liquidity are features of the vehicle, not footnotes.

Giving a new manager three quiet years with no milestones. Three years can be fair. Three years with no interim evidence is how mediocrity becomes furniture.

How I Personally Run The Review

Once a quarter I print a simple sheet: three-year and five-year relative return, discount versus five-year average, ongoing charge, gearing, top ten overlap with the rest of the portfolio, and a one-line thesis. If I cannot write the thesis in one line, that is already a clue.

Then I mark each line hold, watch, or exit. Watch is allowed for one or two quarters, not as a lifestyle. Exit gets a size and a date. I do not always obey my own sheet, which is irritating and very human. The sheet still beats improvising after a bad morning in the market.

When a name is on watch, I read the last two annual reports back to back rather than the latest factsheet. Tone shifts show up there. So do rising related-party comforts, fee debates that go nowhere, and boards that congratulate themselves for “navigating a challenging environment” without changing a single lever.

Replacements Beat Vacuums

If you cut a global muddle, you do not need a perfect substitute on day one, but you do need a direction. Long-only global trusts with simpler rosters have, in several recent stretches, beaten elaborate constructions. UK income investors who leave a chronic laggard often find that a house with a clearer yield process and a willingness to own unfashionable cash generators looks dull until you compare total return.

Asia is the same story with different postcodes. A focused trust that actually compounded is a better teacher than a nostalgic name you remember from a previous cycle. Specialists should be replaced with specialists only if you still want that factor. Otherwise the sale is a chance to reduce complexity. Portfolios rot from too many “interesting” holdings.

Living With Uncertainty Without Freezing

You will get some of these calls wrong. A sold trust will rally. A held trust will keep sliding. That is the job. The aim is not a perfect batting average. The aim is to stop funding strategies you can no longer explain to a sceptical friend in two minutes.

Rhetorical comfort is cheap at the end of an article, so here is the less comforting version. Most dud trusts stay dud longer than the holders expect, and most recoveries that do arrive were visible first in process consistency rather than in a sudden burst of hope. If you remember only one thing, remember that distinction.

Cut when the thesis is broken. Wait when the weather is ugly but the craft is intact. Add only when you can name the reason the market might change its mind. And if you catch yourself reciting the same paragraph year after year, that paragraph is probably the problem.